[Previous Months][Date Index][Thread Index][Join - Register][Login]
  [Message Prev][Message Next][Thread Prev][Thread Next]

Re: [IP] amylien study--More INFO

It is very ironic. My husband bought a tiny bit of Amylin 
Pharmaceuticals stock during the summer of 1998. Jenny was diagnosed 
with Type 1 in February 1999. Their research is very interesting.


email @ redacted wrote:

>>From the website: http://www.amylin.com
>Amylin Pharmaceuticals, Inc. is engaged in the discovery, development and 
>commercialization of potential drug candidates for the treatment of metabolic 
>B  <A HREF="http://www.amylin.com/website/Pipeline/Symlin.htm">SYMLINb" (pramlintide acetate)</A> 
>    SYMLIN is a synthetic version of human amylin, a hormone secreted with 
>insulin by the beta cells in the pancreas. In clinical studies, SYMLIN has 
>exhibited actions that complement those of insulin in maintaining metabolic 
>control. Phase 3 SYMLIN studies demonstrated statistically significant 
>improvements in blood glucose control without weight gain in people with type 
>1 or type 2 diabetes using insulin. These reductions in blood glucose were 
>achieved with no increase in severe hypoglycemic event rates compared to the 
>control group.B  Amylin submitted a New Drug Application (NDA) to the US Food 
>and Drug Administration in December 2000 and received an approvable letter in 
>October 2001 subject to additional clinical work.B  Marketing Authorization 
>Applications for SYMLIN were submitted in Europe in May 2001 and have since 
>been accepted for filing by the EMEA and Swiss Regulatory Authorities   
>for HELP or to subscribe/unsubscribe, contact:
for HELP or to subscribe/unsubscribe, contact: